Esperion Therapeutics (NASDAQ:ESPR) executives told investors the company delivered its “strongest performance to date” in ...

Heart Failure showed that despite a decreased diuretic response in patients with acute decompensated heart failure (ADHF), in ...

Certain medications can interact with multivitamins, making them less effective.

Executives from Esperion Therapeutics (NASDAQ:ESPR) highlighted accelerating revenue growth, plans to expand its commercial ...

Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to ...

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

A secondary analysis of the SOUL trial shows significant improvement in heart failure outcomes with oral semaglutide vs placebo, consistent with the injectable formulation.

Patients already had high NT-proBNP levels at baseline, though, raising questions about the quality of GDMT, Nancy Sweitzer ...

Yet another possibility is that the brain’s habit systems have become very strong, and you—or they—could be entering ...

Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...